A number of research firms have changed their ratings and price targets for Natera (NASDAQ: NTRA):
- 11/6/2024 – Natera was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
- 10/30/2024 – Natera had its price target raised by analysts at Sanford C. Bernstein from $125.00 to $135.00. They now have an “outperform” rating on the stock.
- 10/29/2024 – Natera had its price target raised by analysts at Canaccord Genuity Group Inc. from $145.00 to $150.00. They now have a “buy” rating on the stock.
- 10/25/2024 – Natera was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
- 10/17/2024 – Natera had its price target raised by analysts at Leerink Partners from $140.00 to $150.00. They now have an “outperform” rating on the stock.
- 10/17/2024 – Natera was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
- 10/16/2024 – Natera had its price target raised by analysts at The Goldman Sachs Group, Inc. from $125.00 to $140.00. They now have a “buy” rating on the stock.
- 9/13/2024 – Natera had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $150.00 price target on the stock.
Natera Stock Performance
NTRA stock traded up $2.58 on Wednesday, reaching $126.97. The company’s stock had a trading volume of 1,149,263 shares, compared to its average volume of 1,308,358. Natera, Inc. has a 52 week low of $40.61 and a 52 week high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The company has a market capitalization of $15.70 billion, a P/E ratio of -51.82 and a beta of 1.53. The firm has a fifty day moving average of $123.59 and a two-hundred day moving average of $113.06.
Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the previous year, the business earned ($0.97) EPS. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. As a group, analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.
Insiders Place Their Bets
Hedge Funds Weigh In On Natera
Several hedge funds have recently bought and sold shares of NTRA. Covestor Ltd boosted its holdings in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC boosted its stake in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. CIBC Asset Management Inc increased its position in Natera by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after buying an additional 111 shares during the period. Moss Adams Wealth Advisors LLC lifted its holdings in shares of Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after buying an additional 135 shares during the last quarter. Finally, Private Advisor Group LLC boosted its position in shares of Natera by 5.2% in the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 135 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
- Five stocks we like better than Natera
- The Risks of Owning Bonds
- What a Trump Win Looks Like for the Market Now and Into 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- When to Sell a Stock for Profit or Loss
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Natera Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc and related companies with MarketBeat.com's FREE daily email newsletter.